HC Wainwright Issues Pessimistic Estimate for CLMT Earnings

Calumet Specialty Products Partners, L.P. (NASDAQ:CLMT - Free Report) - Equities researchers at HC Wainwright decreased their Q2 2025 earnings per share estimates for shares of Calumet Specialty Products Partners in a report released on Monday, May 12th. HC Wainwright analyst A. Dayal now expects that the oil and gas company will earn ($0.40) per share for the quarter, down from their previous forecast of ($0.34). HC Wainwright currently has a "Buy" rating and a $33.00 target price on the stock. The consensus estimate for Calumet Specialty Products Partners' current full-year earnings is ($3.02) per share. HC Wainwright also issued estimates for Calumet Specialty Products Partners' Q3 2025 earnings at ($0.27) EPS, Q4 2025 earnings at ($0.17) EPS, FY2025 earnings at ($1.88) EPS, FY2026 earnings at ($0.15) EPS, FY2027 earnings at $0.80 EPS and FY2028 earnings at $1.69 EPS.

Calumet Specialty Products Partners (NASDAQ:CLMT - Get Free Report) last issued its earnings results on Friday, May 9th. The oil and gas company reported ($1.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by ($0.62). The business had revenue of $993.90 million during the quarter, compared to the consensus estimate of $899.62 million. The firm's quarterly revenue was down 1.2% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.51) EPS.

A number of other equities analysts have also recently weighed in on the company. Bank of America started coverage on Calumet Specialty Products Partners in a report on Tuesday, May 13th. They set a "buy" rating and a $15.00 price target for the company. Wells Fargo & Company reduced their price target on Calumet Specialty Products Partners from $23.00 to $21.00 and set an "overweight" rating on the stock in a research report on Wednesday, May 14th. TD Cowen lowered Calumet Specialty Products Partners from a "buy" rating to a "hold" rating and cut their target price for the stock from $26.00 to $16.00 in a research report on Tuesday, March 4th. The Goldman Sachs Group cut their target price on Calumet Specialty Products Partners from $16.00 to $14.00 and set a "buy" rating on the stock in a research report on Wednesday, April 30th. Finally, UBS Group raised Calumet Specialty Products Partners from a "sell" rating to a "neutral" rating and cut their target price for the stock from $15.00 to $12.00 in a research report on Monday, March 17th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company's stock. According to MarketBeat.com, Calumet Specialty Products Partners currently has an average rating of "Hold" and a consensus target price of $18.50.

Calumet Specialty Products Partners Stock Performance

Shares of NASDAQ CLMT traded down $0.02 during mid-day trading on Wednesday, reaching $13.71. 134,064 shares of the company's stock were exchanged, compared to its average volume of 891,952. The firm has a market capitalization of $1.18 billion, a price-to-earnings ratio of -4.95 and a beta of 0.89. Calumet Specialty Products Partners has a 52-week low of $7.68 and a 52-week high of $25.29. The company's 50-day moving average is $11.37 and its 200-day moving average is $16.28.

Insider Transactions at Calumet Specialty Products Partners

In other news, CFO David Lunin bought 2,500 shares of the business's stock in a transaction that occurred on Tuesday, March 4th. The stock was purchased at an average price of $13.05 per share, with a total value of $32,625.00. Following the purchase, the chief financial officer now owns 2,500 shares of the company's stock, valued at $32,625. This trade represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Stephen P. Mawer sold 3,655 shares of the business's stock in a transaction dated Tuesday, April 22nd. The shares were sold at an average price of $9.29, for a total transaction of $33,954.95. Following the completion of the transaction, the director now directly owns 283,652 shares of the company's stock, valued at $2,635,127.08. The trade was a 1.27% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 2.91% of the company's stock.

About Calumet Specialty Products Partners

Calumet, Inc engages in the manufacturing, formulating, and marketing of a diversified slate of specialty branded products and renewable fuels to customers across a broad range of consumer-facing and industrial markets. It operates through the following segments: Specialty Products & Solutions, Performance Brands, Montana/Renewables, and Corporate.